利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1636 条记录 (耗时 0.025 秒)

    TAK1-D MEDIATED INDUCTION OF CELL DEATH IN HUMAN CANCER CELLS BY SPECIFIC SEQUENCE SHORT DOUBLE STRANDED RNAs
    32.
    发明申请
    TAK1-D MEDIATED INDUCTION OF CELL DEATH IN HUMAN CANCER CELLS BY SPECIFIC SEQUENCE SHORT DOUBLE STRANDED RNAs 审中-公开
    TAK1-D介导诱导人类癌细胞细胞死亡特异性序列短双链RNA

    公开(公告)号：WO2009097351A2

    公开(公告)日：2009-08-06

    申请号：PCT/US2009/032269

    申请日：2009-01-28

    申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  KODYM, Reinhard ,  STORY, Michael

    发明人： KODYM, Reinhard ,  STORY, Michael

    IPC分类号： A61K31/7105 ,  A61P35/00

    CPC分类号： A61K31/7105 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

    摘要： The splicing variant D of the TAKl gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAKl-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK but not the NFKB pathway. The current invention therefore provides a method of inducing apoptosis and/or cell cycle arrest in a cancer cell comprising contacting said cell with an agonist of Takl-D function. The invention further provides a method of modulating inflammation and the treatment of cancer by the administration of an agonist of Takl-D function or expression. In yet another aspect, the invention provides a method of inducing p38 MAPK and SAPK/JNK signaling in a cell comprising contacting said cell with an agonist of Takl-D function or expression.

    摘要翻译： TAK1基因的剪接变体D以序列特异性方式被短双链RNA激活。 TAK1-D的激活导致p38MAPK和SAPK / JNK的下游激活，而不是NFκB途径。 因此，本发明提供了诱导癌细胞凋亡和/或细胞周期停滞的方法，包括使所述细胞与Takl-D功能的激动剂接触。 本发明还提供了通过施用Takl-D功能或表达的激动剂来调节炎症和治疗癌症的方法。 在另一方面，本发明提供在细胞中诱导p38MAPK和SAPK / JNK信号传导的方法，包括使所述细胞与Takl-D功能或表达的激动剂接触。

    NUCLEIC ACID COMPOUNDS FOR INHIBITING CTNNB1 GENE EXPRESSION AND USES THEREOF
    39.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING CTNNB1 GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制CTNNB1基因表达的核酸化合物及其用途

    公开(公告)号：WO2008109460A4

    公开(公告)日：2009-03-12

    申请号：PCT/US2008055532

    申请日：2008-02-29

    申请人： NASTECH PHARM CO ,  QUAY STEVEN C ,  MCSWIGGEN JAMES ,  VAISH NARENDRA K ,  AHMADIAN MOHAMMAD

    发明人： QUAY STEVEN C ,  MCSWIGGEN JAMES ,  VAISH NARENDRA K ,  AHMADIAN MOHAMMAD

    IPC分类号： C12N15/113

    CPC分类号： C12N15/1135 ,  C12N15/113 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3515 ,  C12N2310/3521

    摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing CTNNB1 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a CTNNB1 mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a CTNNBl gene in a cell or in a subject to treat a CTNNB1 -related disease.

    摘要翻译： 本公开提供能够降低或沉默CTNNB1基因表达的meroduplex核糖核酸分子（mdRNA）。 本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个不重叠的双链区域，其中一条链与CTNNB1 mRNA互补。 此外，meroduplex可以具有至少一个用5-甲基尿苷取代的尿苷，被锁定的核酸替代的核苷，或任选的其它修饰，以及它们的任何组合。 还提供减少细胞或受试者中CTNNB1基因表达以治疗CTNNB1相关疾病的方法。